Hepatic DPP4 DNA methylation associates with fatty liver

Diabetes

Volumn 66, Issue 1, 2017, Pages 25-35

  Baumeier, Christian ^a,b   Saussenthaler, Sophie ^a,b   Kammel, Anne ^a,b   Jähnert, Markus ^a,b   Schlüter, Luisa ^a,b   Hesse, Deike ^a,b   Canouil, Mickaël ^c,d,e   Lobbens, Stephane ^c,d,e   Caiazzo, Robert ^d,e,f   Raverdy, Violeta ^d,e,f   Pattou, François ^d,e,f   Nilsson, Emma ^g   Pihlajamäki, Jussi ^h,i   Ling, Charlotte ^g   Froguel, Philippe ^c,d,e,j   Schürmann, Annette ^a,b   Schwenk, Robert W ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c INSTITUT PASTEUR DE LILLE   (France)

^d UNIV LILLE   (France)

^e European Genomic Institute for Diabetes   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g LUND UNIVERSITY DIABETES CENTRE   (Sweden)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DNA; GLUCOSE; LIVER ENZYME; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; COMPARATIVE STUDY; CONTROLLED STUDY; CPG ISLAND; DIET INDUCED OBESITY; DISEASE PREDISPOSITION; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; FAT CONTENT; FATTY LIVER; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIPID LIVER LEVEL; LIPOGENESIS; LIVER BIOPSY; LIVER CELL; LIVER LEVEL; MALE; METABOLIC PARAMETERS; MOLECULAR PATHOLOGY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; CPG ISLANDS; DIPEPTIDYL PEPTIDASE 4; DNA METHYLATION; FATTY LIVER; GENE EXPRESSION REGULATION; GLUCOSE; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 85007320568     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1716     Document Type: Article

References (39)

1. Lambeir A-M, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-294
2. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-607
3. Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol 2016;185:1-21
4. Röhrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett 2014;588:3870-3877
5. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-1925
6. Sell H, Blüher M, Klöting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013;36:4083-4090
7. Dunmore SJ, Brown JEP. The role of adipokines in β-cell failure of type 2 diabetes. J Endocrinol 2013;216:T37-T45
8. Röhrborn D, Brückner J, Sell H, Eckel J. Reduced DPP4 activity improves insulin signaling in primary human adipocytes. Biochem Biophys Res Commun 2016;471:348-354
9. Wronkowitz N, Görgens SW, Romacho T, et al. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 2014;1842:1613-1621
10. Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 2012;5:729-733
11. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-1172
12. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006;155:485-493
13. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007;6:242-250
14. Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010;5:e12226
15. Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:7356-7365
16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
17. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000;97:6874-6879
18. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084
19. Kern M, Klöting N, Niessen HG, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012;7:e38744
20. Aroor AR, Habibi J, Ford DA, et al. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 2015;64:1988-2001
21. Brumbaugh DE, Friedman JE. Developmental origins of nonalcoholic fatty liver disease. Pediatr Res 2014;75:140-147
22. Vickers MH. Early life nutrition, epigenetics and programming of later life disease. Nutrients 2014;6:2165-2178
23. U. S. Office of Science and Technology Policy. Laboratory animal welfare; U. S. government principles for the utilization and care of vertebrate animals used in testing, research and training; notice. Fed Regist 1985;50:20864-20865
24. Lönnqvist F, Nordfors L, Jansson M, Thörne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997;99:2398-2404
25. Chen W, Hoo RL, Konishi M, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 2011;286:34559-34566
26. Winkler R, Benz V, Clemenz M, et al. Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes 2012;61:513-523
27. Hesse D, Radloff K, Jaschke A, et al. Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly. J Lipid Res 2014;55:41-52
28. Schwenk RW, Jonas W, Ernst SB, Kammel A, Jähnert M, Schürmann A. Diet-dependent alterations of hepatic Scd1 expression are accompanied by differences in promoter methylation. Horm Metab Res 2013;45:786-794
29. Schwenk RW, Angin Y, Steinbusch LKM, et al. Overexpression of vesicleassociated membrane protein (VAMP) 3, but not VAMP2, protects glucose transporter (GLUT) 4 protein translocation in an in vitro model of cardiac insulin resistance. J Biol Chem 2012;287:37530-37539
30. Kammel A, Saussenthaler S, Jähnert M, et al. Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice. Hum Mol Genet 2016;25:2588-2599
31. Wu JC, Merlino G, Fausto N. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 1994;91:674-678
32. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015;149:379-388; quiz e15-e16
33. Männistö VT, Simonen M, Hyysalo J, et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int 2015;35:1853-1861
34. Männistö VT, Simonen M, Soininen P, et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res 2014;55:2676-2684
35. Nilsson E, Matte A, Perfilyev A, et al. Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels. J Clin Endocrinol Metab 2015;100:E1491-E1501
36. Koza RA, Nikonova L, Hogan J, et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS Genet 2006;2:e81
37. Li L-C, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-1431
38. Turcot V, Bouchard L, Faucher G, et al. DPP4 gene DNA methylation in the omentum is associated with its gene expression and plasma lipid profile in severe obesity. Obesity (Silver Spring) 2011;19:388-395
39. Turcot V, Tchernof A, Deshaies Y, et al. Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome. Diabetol Metab Syndr 2013;5:4